- Home
- EPOW vs CUE Comparison
EPOW vs CUE Comparison
Compare EPOW & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EPOW | CUE |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.7M | 49.6M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | EPOW | CUE |
|---|---|---|
| Price | $0.96 | $0.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 249.6K | 249.2K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $64,997,741.00 | $7,100,000.00 |
| Revenue This Year | N/A | $36.58 |
| Revenue Next Year | N/A | $32.10 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 44.28 | N/A |
| 52 Week Low | $0.73 | $0.47 |
| 52 Week High | $1.86 | $1.75 |
Technical Indicators
Market Signals| Indicator | EPOW | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 33.13 | 29.93 |
| Support Level | $1.00 | $0.47 |
| Resistance Level | $1.41 | $0.51 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 7.82 | 10.78 |
Price Performance
Historical ComparisonAbout EPOW Sunrise New Energy Co. Ltd
Sunrise New Energy Co Ltd is engaged in the manufacturing and sale of graphite anode material for EVs and other lithium-ion batteries. The Company's joint venture is in the construction of a manufacturing plant in Guizhou Province. The plant runs on inexpensive electricity from renewable sources that enables the group to be a low-cost and low environmental impact producer of graphite anode material, Its products include GS-1, GS-2, GS-3, GZD-1, GLD-1, and GZ-1.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.